PT - JOURNAL ARTICLE AU - RA-MAP Consortium AU - Brian Tom TI - Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study AID - 10.1101/2020.03.08.20028142 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.08.20028142 4099 - http://medrxiv.org/content/early/2020/03/12/2020.03.08.20028142.short 4100 - http://medrxiv.org/content/early/2020/03/12/2020.03.08.20028142.full AB - Background To characterize disease course and remission in a longitudinal observational study of newly diagnosed, initially treatment naïve patients with seropositive rheumatoid arthritis (RA).Methods Patients with early untreated seropositive RA were recruited from 28 UK centres. Multiple clinical and laboratory measures were collected every 3 months for up to 18 months. Disease activity was measured using DAS28-CRP and SDAI. Logistic regression models examined clinical predictors of 6-month remission and latent class mixed models characterized disease course.Results We enrolled 275 patients of whom 267 met full eligibility and provided baseline data. According to SDAI definition, 24.3% attained 6-month remission. Lower baseline HAQ and SDAI predicted 6-month remission (p=0.002 and 0.021). Alcohol intake and baseline prescribing of methotrexate with a second DMARD (versus monotherapy without glucocorticoids) were also predictive. Three distinct SDAI trajectory subpopulations emerged; corresponding to an Inadequate Responder group (6.5%), and Higher and Lower Baseline Activity Responder groups (22.4% and 71.1%). Baseline HAQ and SF-36 MCS only distinguished these groups. Additionally a number of baseline clinical predictors correlated with disease activity severity within subpopulations. Beneficial effects of alcohol intake were found across subpopulations.Conclusions Three distinct disease trajectory subpopulations were identified. Differential effects of functional and mental well-being, alcohol consumption and baseline RA medication prescribing on disease activity severity were found across subpopulations. Heterogeneity across trajectories cannot be fully explained by baseline clinical predictors. Biological markers collected early in disease course (within 6 months) may help patient management and to better target existing and novel therapies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN28793839Clinical Protocols http://www.isrctn.com/ISRCTN28793839 Funding StatementThis study was funded by the MRC/ABPI Inflammation and Immunology Initiative Grant (MRC reference numbers: G1001516 and G1001518). Dr Brian Tom is supported by the UK Medical Research Council (Unit Programme number MC_UP_1302/3 and MC_UU_00002/2).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available through the RA-MAP Sample and Data Access Committee. Contact: Dr Dennis Lendrem (dennis.lendrem{at}ncl.ac.uk)